1. Home
  2. CABA vs MGYR Comparison

CABA vs MGYR Comparison

Compare CABA & MGYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CABA
  • MGYR
  • Stock Information
  • Founded
  • CABA 2017
  • MGYR 1922
  • Country
  • CABA United States
  • MGYR United States
  • Employees
  • CABA N/A
  • MGYR N/A
  • Industry
  • CABA Biotechnology: Biological Products (No Diagnostic Substances)
  • MGYR Savings Institutions
  • Sector
  • CABA Health Care
  • MGYR Finance
  • Exchange
  • CABA Nasdaq
  • MGYR Nasdaq
  • Market Cap
  • CABA 118.8M
  • MGYR 98.9M
  • IPO Year
  • CABA 2019
  • MGYR 2006
  • Fundamental
  • Price
  • CABA $1.79
  • MGYR $16.09
  • Analyst Decision
  • CABA Strong Buy
  • MGYR
  • Analyst Count
  • CABA 8
  • MGYR 0
  • Target Price
  • CABA $18.88
  • MGYR N/A
  • AVG Volume (30 Days)
  • CABA 2.5M
  • MGYR 9.7K
  • Earning Date
  • CABA 08-07-2025
  • MGYR 07-24-2025
  • Dividend Yield
  • CABA N/A
  • MGYR 1.60%
  • EPS Growth
  • CABA N/A
  • MGYR 19.38
  • EPS
  • CABA N/A
  • MGYR 1.43
  • Revenue
  • CABA N/A
  • MGYR $34,067,000.00
  • Revenue This Year
  • CABA N/A
  • MGYR N/A
  • Revenue Next Year
  • CABA N/A
  • MGYR N/A
  • P/E Ratio
  • CABA N/A
  • MGYR $11.40
  • Revenue Growth
  • CABA N/A
  • MGYR 12.12
  • 52 Week Low
  • CABA $0.99
  • MGYR $10.67
  • 52 Week High
  • CABA $9.25
  • MGYR $16.31
  • Technical
  • Relative Strength Index (RSI)
  • CABA 47.69
  • MGYR 72.48
  • Support Level
  • CABA $1.56
  • MGYR $15.69
  • Resistance Level
  • CABA $2.02
  • MGYR $16.16
  • Average True Range (ATR)
  • CABA 0.24
  • MGYR 0.19
  • MACD
  • CABA -0.06
  • MGYR -0.02
  • Stochastic Oscillator
  • CABA 22.33
  • MGYR 94.55

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

About MGYR Magyar Bancorp Inc.

Magyar Bancorp Inc is a mid-tier stock holding company. The Company offers a full array of commercial and retail financial services, including the taking of time, savings and demand deposits; the making of commercial, consumer and home equity loans; and the provision of other financial services. The business consists of getting retail deposits from the general public in the areas surrounding the main office in New Brunswick, New Jersey and branch offices located in Middlesex and Somerset Counties, New Jersey, and investing those deposits, together with funds generated from operations and wholesale funding, in residential mortgage loans, home equity loans, home equity lines of credit, commercial real estate loans, commercial business loans, Small Business Administration loans.

Share on Social Networks: